ERxin(ERxin) - 药物靶点：α-adrenergic receptor_专利_临床

概要

基本信息

药物类型

小分子化药

别名-

靶点

α-adrenergic receptor

作用机制

α-adrenergic receptor拮抗剂(α-肾上腺素能受体家族拮抗剂)

治疗领域

泌尿生殖系统疾病

在研适应症-

非在研适应症

勃起功能障碍

原研机构

Repros Therapeutics, Inc.

在研机构-

非在研机构

Repros Therapeutics, Inc.

最高研发阶段终止临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

100 项与 ERxin 相关的临床结果

登录后查看更多信息

100 项与 ERxin 相关的转化医学

登录后查看更多信息

100 项与 ERxin 相关的专利（医药）

登录后查看更多信息

1

项与 ERxin 相关的文献（医药）

1992-05-01·Zhonghua yi xue za zhi

[Dynamic study on superficial blood flow in patients with acute myocardial infarction].

Article

作者: Fu, H

Fourteen points superficial bloodflow (SBF) of the skin and tongue in 55 patients with acute myocardial infarction (AMI) were measured at 12, 24, 36, 48, 60 hours and 3, 5, 7, 10, 14, 21, 28 days after AMI by LDF (PF2). The dynamic study on multiple points SBF of 576 times showed that (1) The mean SBF of skin was 1.0 +/- 0.04 (V) at 12 hours after AMI. It occupied 70.5% in the normal control. After therapy at 48 hours of AMI, the mean SBF was increased to 1.20 +/- 0.03 (V), and approximated 85.9% of the control. (2) The mean SBF in patients with cardiogenic shock was 1.04 +/- 0.05 (V), and it was significantly lower than that without complications (P less than 0.01). The mean SBF showed a negative correlation with the nailfold microcirculatory values (P less than 0.0025). There was a negative correlation between "Tanzhong" SBF and cardiac muscle enzyme CPK, GOT, LDH (P less than 0.05). (3) The SBF of acupuncture point "Tanzhong, Erxin" related to the heart might more sensitively represent the cardiac condition in AMI. (4) The SBF of tongue was negatively correlated with GOT (P less than 0.05). (5) Continual peripheral microcirculatory observation and electrocardiographic monitoring would be helpful in the diagnosis and treatment of earlier complications of AMI in order to reduce the mortality.

100 项与 ERxin 相关的药物交易

登录后查看更多信息